This stock is now available for trading
Looking to invest? Visit our full stock guide for Medline (MDLN) to see live share price, how to buy shares and key market updates.

By
Matt MiczulskiUpdated
Looking to invest? Visit our full stock guide for Medline (MDLN) to see live share price, how to buy shares and key market updates.
Medline is expected to go public soon. Here's what we know about the IPO — and how to buy Medline stock when it's available.
Medline said on Monday, December 8, 2025, that it was targeting an up to $55.3 billion valuation in its IPO. The company is seeking to raise up to $5.37 billion by offering 179 million shares priced between $26 and $30 apiece.(1)
Medline posted net income of $977 million for the nine months ending September 27, up from $911 million in the same period last year. Net sales rose to $20.6 billion from $18.7 billion.
The company will list on the Nasdaq under the trading symbol "MDLN".
Final pricing has yet to be announced and the expected IPO date is December 17, 2025. We'll update this page with more information as it becomes available.
Once Medline goes public, you'll need a brokerage account to invest. Consider opening a brokerage account today so you're ready as soon as the stock hits the market.
Top pick for banking + investing in one app
Get 12 free shares
Top pick for integrated stock & crypto investing
T&Cs apply
It's impossible to predict how any stock will perform — and IPOs can be particularly volatile. Looking at the performance of similar companies can help you decide if now is a good time to buy Medline stock.
See how the following stocks are performing, and view details like market capitalization, the price-to-earnings (P/E) ratio, price/earnings-to-growth (PEG) ratio and dividend yield.Looking for other options? Check out these similar products.
How we picked theseThe Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on eight different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Finder writers are subject matter experts and use primary sources, in-depth research and interviews with other experts to ensure you're getting accurate, up-to-date information. Articles are fact checked in line with our editorial guidelines.
Matt Miczulski is an investments editor and market analyst at Finder. With over 450 bylines, Matt dissects and reviews brokers and investing platforms to expose perks and pain points, explores investment products and concepts and covers market news, making investing more accessible and helping readers to make informed financial decisions. Before joining Finder in 2021, Matt covered everything from finance news and banking to debt and travel for FinanceBuzz. His expertise and analysis on investing and other financial topics has been featured on Yahoo Finance, CBS, MSN, Best Company and Consolidated Credit, among others. Matt holds a BA in history from William Paterson University. See full bio
Everything we know about the Kalshi IPO, plus information on how to buy in.
Everything we know about the Oura IPO, plus information on how to buy in.
Everything we know about the Pershing Square Capital Management IPO, plus information on how to buy in.
Everything we know about the Wealthfront IPO, plus information on how to buy in.
Everything we know about the Gloo IPO, plus information on how to buy in.
Everything we know about the Figure IPO, plus information on how to buy in.
Everything we know about the Klarna IPO, plus information on how to buy in.
Finder is a comparison platform and information service designed to help you make better decisions. To keep our service free, we receive compensation from the companies whose products or services we feature on our site.
We may be paid when you click on a link, submit an application, or open an account.
Our commercial arrangements affect which products we write about, as well as the inclusion, order, position and placement of products on our site. They do not influence our independent assessments or editorial views, which are based on research and expert analysis conducted by our editorial team.
The inclusion of a provider or product in our content, or the order in which products appear in tables or lists, is not an endorsement or recommendation from us.
We compare a wide range of products, providers and services, but we don't cover the whole market. Not every company or offer available is included on our site, and other options may be available to you.
The information we provide is general in nature and is not financial, investment, tax or legal advice. Consider your own circumstances and read the provider's terms and conditions before making a decision.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.